BlackRock Fund Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$78.7M	Buy	2,100,902 +173,565	+9%	+$7.27M	0.01%	1382
2016 Q3	$131M	Buy	1,927,337 +56,455	+3%	+$3.98M	0.03%	875
2016 Q2	$104M	Buy	1,870,882 +32,506	+2%	+$2.05M	0.02%	946
2016 Q1	$115M	Buy	1,838,376 +112,252	+7%	+$7.46M	0.03%	837
2015 Q4	$162M	Sell	1,726,124 -177,587	-9%	-$16.5M	0.04%	605
2015 Q3	$153M	Buy	1,903,711 +121,946	+7%	+$13.5M	0.04%	604
2015 Q2	$214M	Buy	1,781,765 +89,153	+5%	+$10.7M	0.05%	429
2015 Q1	$177M	Buy	1,692,612 +237,280	+16%	+$24M	0.04%	572
2014 Q4	$141M	Sell	1,455,332 -10,963	-0.7%	-$1.02M	0.03%	674
2014 Q3	$115M	Buy	1,466,295 +58,472	+4%	+$3.77M	0.03%	735
2014 Q2	$88.9M	Sell	1,407,823 -902,180	-39%	-$53.6M	0.03%	971
2014 Q1	$155M	Buy	2,310,003 +96,481	+4%	+$7.47M	0.05%	519
2013 Q4	$142M	Sell	2,213,522 -35,480	-2%	-$2.12M	0.04%	571
2013 Q3	$144M	Buy	2,249,002 +337,517	+18%	+$16.8M	0.05%	490
2013 Q2	$59.3M	Buy	+1,911,485	New	+$50.9M	0.02%	1078